Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Clarinex extension

This article was originally published in The Tan Sheet

Executive Summary

FDA has approved Clarinex-D 12-Hour extended release tablets, Schering announces Feb. 1. The new formulation (desloratadine 2.5 mg/pseudoephedrine sulfate 120 mg) features a bi-layer tablet delivery system to control the release of the pseudoephedrine. The drug will be available in March, in time for allergy season, Schering notes. Separately, Claritin sales decreased 29% to $54 mil. during the fourth quarter of 2005, the company reports in an earnings call Jan. 30. Decreased Claritin-D (loratadine/pseudoephedrine) sales were attributed to PSE retail restrictions. Lower Claritin revenues, as well as a dip in sales of other pseudoephedrine-containing products contributed to a 9% decline in Consumer Health Care sales from the prior-year period to $198 mil. for the quarter. Adjusted net sales for the firm overall increased 13% to $2.7 bil. in the quarter, signaling the firm's move "from survive mode into thrive mode," CEO Fred Hassan states...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS099063

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel